150 related articles for article (PubMed ID: 11721966)
1. A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia.
Fukushima T; Yamashita T; Goto N; Ueda T; Okabe KI; Kuraishi Y; Ohno R; Urabe A; Ogawa M
Int J Hematol; 2001 Oct; 74(3):297-302. PubMed ID: 11721966
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
Tamura K
Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
[TBL] [Abstract][Full Text] [Related]
3. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
[TBL] [Abstract][Full Text] [Related]
4. Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course.
Eksborg S; Björkholm M; Hast R; Fagerlund E
Anticancer Drugs; 1997 Jan; 8(1):42-7. PubMed ID: 9147610
[TBL] [Abstract][Full Text] [Related]
5. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
[TBL] [Abstract][Full Text] [Related]
6. Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study.
Camaggi CM; Strocchi E; Carisi P; Martoni A; Tononi A; Guaraldi M; Strolin-Benedetti M; Efthymiopoulos C; Pannuti F
Cancer Chemother Pharmacol; 1992; 30(4):307-16. PubMed ID: 1643700
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats.
Zara GP; Bargoni A; Cavalli R; Fundarò A; Vighetto D; Gasco MR
J Pharm Sci; 2002 May; 91(5):1324-33. PubMed ID: 11977108
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and toxicity of idarubicin in the rat.
Kuhlmann O; Hofmann S; Weiss M
Eur J Drug Metab Pharmacokinet; 2001; 26(4):215-9. PubMed ID: 11808862
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia.
Pea F; Damiani D; Michieli M; Ermacora A; Baraldo M; Russo D; Fanin R; Baccarani M; Furlanut M
Eur J Clin Pharmacol; 1999 Jul; 55(5):361-8. PubMed ID: 10456485
[TBL] [Abstract][Full Text] [Related]
12. Effect of PSC 833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells.
Fukushima T; Yamashita T; Yoshio N; Misaki H; Yamauchi T; Imamura S; Urasaki Y; Ueda T
Leuk Res; 1999 Jan; 23(1):37-42. PubMed ID: 9933133
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic comparison of 120-hour infusion versus hyperfractionated oral administration of idarubicin.
Toffoli G; Sorio R; Basso B; Aita P; Corona G; Rupolo M; Boiocchi M
J Chemother; 2004 Apr; 16(2):193-200. PubMed ID: 15216956
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients.
Robert J; Rigal-Huguet F; Hurteloup P
Hematol Oncol; 1992; 10(2):111-6. PubMed ID: 1592361
[TBL] [Abstract][Full Text] [Related]
15. Determination of idarubicin and idarubicinol in plasma by capillary electrophoresis.
Hempel G; Haberland S; Schulze-Westhoff P; Möhling N; Blaschke G; Boos J
J Chromatogr B Biomed Sci Appl; 1997 Sep; 698(1-2):287-92. PubMed ID: 9367219
[TBL] [Abstract][Full Text] [Related]
16. Influence of idarubicinol on the antileukemic effect of idarubicin.
Fukushima T; Kawai Y; Urasaki Y; Yoshida A; Ueda T; Nakamura T
Leuk Res; 1994 Dec; 18(12):943-7. PubMed ID: 7996875
[TBL] [Abstract][Full Text] [Related]
17. High-performance liquid chromatographic analysis of idarubicin and fluorescent metabolites in biological fluids.
Camaggi CM; Carisi P; Strocchi E; Pannuti F
Cancer Chemother Pharmacol; 1992; 30(4):303-6. PubMed ID: 1643699
[TBL] [Abstract][Full Text] [Related]
18. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
Leukemia; 1997 Dec; 11 Suppl 5():S15-21. PubMed ID: 9436933
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit.
Looby M; Linke R; Weiss M
Cancer Chemother Pharmacol; 1997; 39(6):554-6. PubMed ID: 9118470
[TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis by idarubicin: how important is the plasma peak?
Gieseler F; Clark M; Stiebeling K; Puschmann M; Valsamas S
Int J Clin Pharmacol Ther; 2000 Apr; 38(4):217-21. PubMed ID: 10783832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
